Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study

Kyrkos, Margaritis J.; Papavasiliou, Kyriakos A.; Kenanidis, Eustathios; Tsiridis, Eleftherios; Sayegh, Fares E.; Kapetanos, G.

doi:10.1016/j.joca.2013.03.011

Cited by 22 publications

(17 citation statements)

References 51 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies carried out in the canine Pond-Nuki model demonstrated that tiludronate exerts beneficial effects on gait disability and joint symptoms by improving some OA structural changes and reducing the synthesis of catabolic and inflammatory mediators [27]. Similar findings have been reported for calcitonin and estrogen use in different OA experimental models [16,[28][29][30][31][32][33][34][35][36][37][38][39][40]. Calcitonin prevented subchondral bone resorption and trabecular thinning associated to reduced cartilage degradation in a canine ACLT-induced OA model [28,29].…”

Section: Animal Studiessupporting

confidence: 65%

An OA phenotype may obtain major benefit from bone-acting agents

Roman‐Blas

Castañeda

Largo

et al. 2014

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Section: Animal Studiessupporting

confidence: 65%

An OA phenotype may obtain major benefit from bone-acting agents

Roman‐Blas

Castañeda

Largo

et al. 2014

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

“…sCT administered intranasally reduced both subchondral bone remodelling and cartilage lesions in the early stages of OA 96 . Other studies reported beneficial effects following prophylactic and therapeutic intramuscular administration of sCT in cartilage lesions and bone turnover in the surgically induced OA rabbit model 97 . In a canine ACLT OA model 98 , subcutaneous injections of calcitonin under therapeutic conditions also reduced the progression of osteoarthritic cartilage and subchondral bone changes as well as the levels of serum markers of bone resorption.…”

Section: Calcitoninmentioning

confidence: 96%

Bone–cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies

Yuan

Meng

Wang

et al. 2014

Osteoarthritis and Cartilage

248

232

View full text Add to dashboard Cite

Currently, osteoarthritis (OA) is considered a disease of the entire joint, which is not simply a process of wear and tear but rather abnormal remodelling and joint failure of an organ. The bone-cartilage interface is therefore a functioning synergistic unit, with a close physical association between subchondral bone and cartilage suggesting the existence of biochemical and molecular crosstalk across the OA interface. The crosstalk at the bone-cartilage interface may be elevated in OA in vivo and in vitro. Increased vascularisation and formation of microcracks associated with abnormal bone remodelling in joints during OA facilitate molecular transport from cartilage to bone and vice versa. Recent reports suggest that several critical signalling pathways and biological factors are key regulators and activate cellular and molecular processes in crosstalk among joint compartments. Therapeutic interventions including angiogenesis inhibitors, agonists/antagonists of molecules and drugs targeting bone remodelling are potential candidates for this interaction. This review summarised the premise for the presence of crosstalk in bone-cartilage interface as well as the current knowledge of the major signalling pathways and molecular interactions that regulate OA progression. A better understanding of crosstalk in bone-cartilage interface may lead to development of more effective strategies for treating OA patients.

show abstract

“…A healed site was defined as a complete iso-opaque bridging bone callus connecting the two cortices (31). The osteo arthritis scale employed was modified from human and ca-nine osteoarthritis grading scales described previously in the literature (32)(33)(34). The scale used combined findings from the radiographs to describe the following grading scale: 0 = no evidence of joint effusion, osteophytosis, intra-articular mineralization or subchondral bone sclerosis; 1 = joint effusion present, loss or degeneration of articular cartilage; 2 = joint effusion and subchondral bone sclerosis present, minimal to mild osteophytosis; 3 = moderate to severe osteophytosis, intra-articular mineralization present or both; and 4 = appearance of subchondral cysts.…”

Section: Outcome Assessmentmentioning

confidence: 99%

Preoperative low level laser therapy in dogs undergoing tibial plateau levelling osteotomy: A blinded, prospective, randomized clinical trial

Rogatko¹,

Baltzer²,

Tennant³

2017

Vet Comp Orthop Traumatol

View full text Add to dashboard Cite

Twenty-seven dogs (27 stifles) were included and no major complications occurred. At eight weeks postoperatively, a significant difference in peak vertical force analysis was noted between the LLLT (39.6% ± 4.7%) and sham groups (28.9% ± 2.6%), (p <0.01 Time, p <0.01 L). There were no significant differences noted between groups for all other parameters. The age of dogs in the LLLT group (6.6 ± 1.6 years) was greater than that for the sham group (4.5 ± 2.0, p <0.01). Although not significant, a greater proportion of LLLT dogs (5/8) had healed at the eight-week time point than in the sham group (3/12) despite the age difference (p = 0.11) Clinical significance: The results of this study demonstrate that improved peak vertical force could be related to the preoperative use of LLLT for dogs undergoing TPLO at eight weeks postoperatively. The use of LLLT may improve postoperative return to function following canine osteotomies and its use is recommended.

show abstract

Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study

Abstract: I.M. administration of Calcitonin seems to delay the progress of early-stage osteoarthritic lesions induced by mechanical instability in a rabbit experimental model.

Cited by 22 publications

References 51 publications

An OA phenotype may obtain major benefit from bone-acting agents

An OA phenotype may obtain major benefit from bone-acting agents

Bone–cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies

Preoperative low level laser therapy in dogs undergoing tibial plateau levelling osteotomy: A blinded, prospective, randomized clinical trial

Contact Info

Product

Resources

About